(S)-4-Methylhomoibotenic acid

Discontinued Product

(S)-4-Methylhomoibotenic acid (Cat. No. 0318) has been withdrawn from sale for commercial reasons.
Description: Positional isomer of (S)-AMPA
Chemical Name: (S)-a-Amino-3-hydroxy-4-methyl-5-isoxazolepropionic acid
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for (S)-4-Methylhomoibotenic acid

Isomer of (S)-AMPA. Produces similar but lesser effect.

Technical Data for (S)-4-Methylhomoibotenic acid

M. Wt 186.17
Storage Store at RT
CAS Number 77006-29-2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (S)-4-Methylhomoibotenic acid

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for (S)-4-Methylhomoibotenic acid

References are publications that support the biological activity of the product.

Brauner- Osborne et al (1998) Molecular pharmacology of homologues of ibotenic acid at cloned metabotropic glutamic acid receptors. Eur.J.Pharmacol. 350 311 PMID: 9696422

Christensen et al (1992) Excitatory amino acid receptor ligands. Synthesis and biological activity of 3-isoxazolol amino acids structurally related to homoibotenic acids. J.Med.Chem. 35 3512 PMID: 1383544

View Related Products by Target

Keywords: (S)-4-Methylhomoibotenic acid, (S)-4-Methylhomoibotenic acid supplier, AMPA, Receptors, 0318, Tocris Bioscience

Citations for (S)-4-Methylhomoibotenic acid

Citations are publications that use Tocris products.

Currently there are no citations for (S)-4-Methylhomoibotenic acid.

Reviews for (S)-4-Methylhomoibotenic acid

There are currently no reviews for this product. Be the first to review (S)-4-Methylhomoibotenic acid and earn rewards!

Have you used (S)-4-Methylhomoibotenic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.